Levocabastine
From Wikipedia, the free encyclopedia
|
Levocabastine
|
|
| Systematic (IUPAC) name | |
| 1-[4-cyano-4-(4-fluorophenyl)-cyclohexyl]- 3-methyl-4-phenyl-piperidine-4- carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | R01 S01GX02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C26H29FN2O2 |
| Mol. mass | 420.519 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3 |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
℞ Prescription only |
| Routes | Ophthalmic, intranasal |
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis.
Levocabastine was discovered at Janssen Pharmaceutica in 1979.
[edit] References
- Pipkorn U, Bende M, Hedner J, Hedner T., A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis, Allergy. 1985 Oct;40(7):491-6.
- RxList (2004). Livostin Online, Description, Chemistry, Ingredients - Levocabastine. LIVOSTIN. RxList Inc. Retrieved on 9 October 2005.
- Novartis Pharmaceuticals (March 2002). LIVOSTIN (PDF). Retrieved on August 20, 2006.
- ^ RxMed: Pharmaceutical Information - LIVOSTIN NASAL SPRAY. Retrieved on 13 November 2005.
|
|||||||||||||||||

